// App-Quantinova.ai

3371 : A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project

Researchers

Presenter

  • Anand Tandra

Principal Investigators

  • Robert Z. Gut

  • David L. Cooper

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Novo Nordisk A/S

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Hemophilia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rFVIIa

  • FVIII

Outcome

  • N/A

Study Design

  • observational

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved